Ibalizumab
CD4-directed Blocking Antibody — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: ibalizumab-uiyk, TMB-355, TNX-355, trogarzo
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Ibalizumab is a drug in the CD4-directed Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2018. Its mechanism of action is classified as CD4-directed Antibody Interactions and HIV 1 Post-attachment Fusion Inhibitors. DrugCentral lists 1 molecular target, including CD4. Recorded indications include Human immunodeficiency virus infection.
- Drug class: CD4-directed Blocking Antibody; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor.
- Mechanism of action: CD4-directed Antibody Interactions; HIV 1 Post-attachment Fusion Inhibitors.
- Molecular targets: CD4 (1 listed in DrugCentral).
- Indications: Human immunodeficiency virus infection.
- ATC code: J05AX23 (Other antivirals).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Human immunodeficiency virus infection
Mechanism & targets
| Mechanism of action (MoA) | CD4-directed Antibody Interactions; HIV 1 Post-attachment Fusion Inhibitors |
|---|---|
| Established pharmacologic class | CD4-directed Blocking Antibody; Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| T-cell surface glycoprotein CD4 | CD4 | other | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2019-09-26 | EMA | — | Theratechnologies International Limited | |
| 2018-03-06 | FDA | — | TAIMED BIOLOGICS USA | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AX23 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Other antivirals |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Viral load increased | 206.5 |
| Virologic failure | 90.3 |
| Product dose omission issue | 85.2 |
| Genotype drug resistance test positive | 67.3 |
| Product use in unapproved therapeutic environment | 62.0 |
| Hospitalisation | 55.4 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 680188-33-4 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Ibalizumab used for?
DrugCentral lists the following indications for Ibalizumab: Human immunodeficiency virus infection.
How does Ibalizumab work?
Ibalizumab is classified as CD4-directed Antibody Interactions and HIV 1 Post-attachment Fusion Inhibitors; its molecular targets in DrugCentral include CD4.
When was Ibalizumab first approved?
Ibalizumab was first approved by the FDA in 2018.
What drug class does Ibalizumab belong to?
Ibalizumab is in the CD4-directed Blocking Antibody class.
Browse: all drugs starting with I · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5279 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1743029 — compound record and bioactivity
- DrugBank DB12698 — drug record
- FDA UNII LT369U66CE — substance identity
- DailyMed: FDA labels for Ibalizumab — current prescribing information (label search)
- UniProt P01730 (CD4) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.